References
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67:7-30.
Debes JD, Tindall DJ. The Role of Androgens and The Androgen Receptor in Prostate Cancer. Cancer Lett 2002;187:1-7.
Anderson J. Treatment of Prostate Cancer- The Role of Primary Hormonal Therapy. EAU Update Series 2003;1:32-39.
Lonergan E, Tindall DJ. Androgen Receptor Signaling in Prostate Cancer Development and Progression. J Carcinog 2011;10:20.
Korkmaz CG, Korkmaz KS, Kurys P, et al. Molecular Cloning and Characterization of STAMP2, an Androgen-regulated Six Transmembrane Protein That is Overexpressed in Prostate Cancer. Oncogene 2005;24:4934-4945.
Jin Y, Wang L, Qu S, et al. STAMP2 Increases Oxidative Stress and is Critical for Prostate Cancer. EMBO Mol Med 2015;7:315-331.
Sikkeland J, Sheng X, Jin Y, Saatcioglu F. STAMPing at The Crossroads of Normal Physiology and Disease States. Mol Cell Endocrinol 2016;425:26-36.
Catterall WA. Molecular Properties of Brain Sodium Channels: An Important Target for Anticonvulsant Drugs. Adv Neurol 1999;79:441-456.
Caterina MJ, Schumacher MA, Tominaga M, et al. The Capsaicin Receptor: A Heat-Activated Ion Channel in The Pain Pathway. Nature 1997;389:816-824.
Haass C. Presenile Because of Presenilin: The Presenilin Genes and Early Onset Alzheimer’s Disease. Curr Opin Neurol 1996;9:254-259.
Ordovas JM. ABC1: The Gene for Tangier Disease and Beyond. Nutr Rev 2000;58:76-79.
Arner P, Stenson BM, Dungner E, et al. Expression of Six Transmembrane Protein of Prostate 2 in Human Adipose Tissue Associates with Adiposity and Insulin Resistance. J Clin Endocrinol Metab 2008;93:2249-2254.
Stephan C, Jung K, Diamandis EP, et al. Prostate-Specific Antigen, Its Molecular Forms, and Other Kallikrein Markers for Detection of Prostate Cancer. Urology 2002;59:2-8.
Frendler WP, Rahbar K, Herrmann K, et al. 177Lu- PSMA Radioligand Therapy for Prostate Cancer. J Nucl Med 2017;58:1196-1200.
Baum RP, Kulkarni HR, Schuchardt C, et al. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. J Nucl Med 2016;57:1006-1013.
Kessler C, Pardo A, Tur MK, et al. Novel PSCA Targeting scFv-fusion Proteins for Diagnosis and Immunotherapy of Prostate Cancer. J Cancer Res Clin Oncol 2017;30:2472-2479.
Azumi M, Kobayashi H, Aoki N, et al. Six-transmembrane Epithelial Antigen of The Prostate As An Immunotherapeutic Target For Renal Cell and Bladder Cancer. J Urol 2010;183:2036-2044.
Lindstad T, Qu S, Sikkeland J, et al. STAMP2 Is Required for Human Adipose-Derived Stem Cell Differentiation and Adipocyte-facilitated Prostate Cancer Growth In Vivo. Oncotarget 2017;8:91817-91827.
ten Freyhaus H, Calay ES, Yalcin A, et al. Stamp2 Controls Macrophage Inflammation Through Nicotinamide Adenine Dinucleotide Phosphate Homeostasis and Protects Against Atherosclerosis. Cell Metab 2012;16:81-89.
